Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Neurology Gastroenterology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial Active — Not Recruiting NCT06327971

Enhanced Outcome Prediction in Cutaneous Squamous Cell Carcinoma Using Deep-learning and Computational Histopathology

Enhanced Outcome Prediction in Cutaneous Squamous Cell Carcinoma Using Deep-learning and Computational Histopathology — Active Not Recruiting • Dermatology • NCT06327971.

📅 02 Apr 2026 ⏱ 1 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
NCT ID
NCT06327971
Start
2023-10-20
Completion
2028-10
ClinicaliQ Trial Snapshot
  • Enhanced Outcome Prediction in Cutaneous Squamous Cell Carcinoma Using Deep-learning and Computational Histopathology — Active Not Recruiting • Dermatology • NCT06327971.
  • Review the linked registry entry for study design, population, endpoints, and operational status.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Evaluate a deep-learning model trained on computational histopathology for predicting outcomes in cutaneous squamous cell carcinoma Conditions: Squamous Cell Carcinoma of the Skin Lead Sponsor: Queen Mary University of London Planned Enrollment: 300 participants

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Subcutaneous spesolimab 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over (terminated appraisal)
Dermatology · 08 Apr 2026
This NICE publication is marked as a terminated appraisal, so it functions as a status notice rather than an active treatment recommendation…
View guideline →
Clinical Brief
Topical steroids: introduction of new labelling and a reminder of the possibility of severe side effects, including Topical Steroid Withdrawal Reactions
Dermatology · MHRA · 29 May 2024
Topical steroid products are safe and highly effective treatments for the management of a wide range of inflammatory skin diseases but have…
View brief →
Guideline
Hidradenitis Suppurativa: Assessment and Management (NICE NG73)
Dermatology · 27 Mar 2026
Diagnose hidradenitis suppurativa clinically based on recurrent painful nodules, abscesses, sinus tracts, and scars localised to intertriginous areas (axillae, groin, inframammary folds),…
View guideline →
Guideline
Atopic Eczema in Under 12s: Diagnosis and Management (NICE NG190)
Dermatology · 27 Mar 2026
Diagnose atopic eczema clinically based on itching, typical morphology and distribution, onset before age 2 years, and history of dry skin or…
View guideline →
Clinical Brief
Our skin is falling off and no-one can tell us why
Dermatology · BBC Health · 29 Mar 2026
Topical Steroid Withdrawal: Key Clinical Takeaways TSW is now subject to formal UK research: Growing social media documentation of cases has prompted…
View brief →
Guideline
Non-Melanoma Skin Cancer: Diagnosis and Management (NICE NG12)
Dermatology · 27 Mar 2026
Refer suspected BCC or SCC to specialist dermatology using 2-week wait pathway if diagnosis is clear; use urgent referral for lesions >4…
View guideline →